img

Global Pharmaceutical CDMO Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Pharmaceutical CDMO Market Research Report 2024

A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fieldsproduct development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.
Contract Pharmaceutical Manufacturing is part of CDMO, refers to accept commissioned from pharmaceutical companies, provide the service about API production, FDF production, packaging.
Pharmaceutical companies are likely to outsource a wide range of manufacturing related activities including – primary and secondary packaging, formulation, active ingredient manufacturing, labeling, clinical supplies, sterilization, manufacturing of chemical intermediates, etc. CDMOs support pharmaceutical companies at all stages of the process of making medicinesby providing services in the research and development stages, by offering support in manufacturing, and by providing formulating and finishing processes.
According to MRAResearch’s new survey, global Pharmaceutical CDMO market is projected to reach US$ 217220 million in 2033, increasing from US$ 128270 million in 2022, with the CAGR of 7.7% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pharmaceutical CDMO market research.
The key service providers of the Pharmaceutical CDMO in the world are Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics and Siegfried, among which the market share of the top three service providers exceeds 10%, and Lonza is the largest service provider. The services provided by global pharmaceutical CDMO are mainly distributed in North America, Europe and China, among which the top three regions account for nearly 60% of the market share, and North America is currently the largest service provider. In terms of its service type, the growth rate of FDF CDMO is relatively fast. At present, the market share of API CDMO is the highest, more than 40%, followed by FDF CDMO, packaging CDMO and clinical CDMO. In terms of its application, pharmaceutical company are the largest application field, with a market share of more than 60%, followed by biotechnology company.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Pharmaceutical CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
Segment by Type
API CDMO
FDF CDMO
Packaging CDMO
Clinical CDMO

Segment by Application


Pharmaceutical Company
Biotechnology Company
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pharmaceutical CDMO report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmaceutical CDMO Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 API CDMO
1.2.3 FDF CDMO
1.2.4 Packaging CDMO
1.2.5 Clinical CDMO
1.3 Market by Application
1.3.1 Global Pharmaceutical CDMO Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmaceutical CDMO Market Perspective (2018-2033)
2.2 Pharmaceutical CDMO Growth Trends by Region
2.2.1 Global Pharmaceutical CDMO Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Pharmaceutical CDMO Historic Market Size by Region (2018-2023)
2.2.3 Pharmaceutical CDMO Forecasted Market Size by Region (2024-2033)
2.3 Pharmaceutical CDMO Market Dynamics
2.3.1 Pharmaceutical CDMO Industry Trends
2.3.2 Pharmaceutical CDMO Market Drivers
2.3.3 Pharmaceutical CDMO Market Challenges
2.3.4 Pharmaceutical CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmaceutical CDMO Players by Revenue
3.1.1 Global Top Pharmaceutical CDMO Players by Revenue (2018-2023)
3.1.2 Global Pharmaceutical CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Pharmaceutical CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmaceutical CDMO Revenue
3.4 Global Pharmaceutical CDMO Market Concentration Ratio
3.4.1 Global Pharmaceutical CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical CDMO Revenue in 2022
3.5 Pharmaceutical CDMO Key Players Head office and Area Served
3.6 Key Players Pharmaceutical CDMO Product Solution and Service
3.7 Date of Enter into Pharmaceutical CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmaceutical CDMO Breakdown Data by Type
4.1 Global Pharmaceutical CDMO Historic Market Size by Type (2018-2023)
4.2 Global Pharmaceutical CDMO Forecasted Market Size by Type (2024-2033)
5 Pharmaceutical CDMO Breakdown Data by Application
5.1 Global Pharmaceutical CDMO Historic Market Size by Application (2018-2023)
5.2 Global Pharmaceutical CDMO Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Pharmaceutical CDMO Market Size (2018-2033)
6.2 North America Pharmaceutical CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Pharmaceutical CDMO Market Size by Country (2018-2023)
6.4 North America Pharmaceutical CDMO Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmaceutical CDMO Market Size (2018-2033)
7.2 Europe Pharmaceutical CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Pharmaceutical CDMO Market Size by Country (2018-2023)
7.4 Europe Pharmaceutical CDMO Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceutical CDMO Market Size (2018-2033)
8.2 Asia-Pacific Pharmaceutical CDMO Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Pharmaceutical CDMO Market Size by Region (2018-2023)
8.4 Asia-Pacific Pharmaceutical CDMO Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmaceutical CDMO Market Size (2018-2033)
9.2 Latin America Pharmaceutical CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Pharmaceutical CDMO Market Size by Country (2018-2023)
9.4 Latin America Pharmaceutical CDMO Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceutical CDMO Market Size (2018-2033)
10.2 Middle East & Africa Pharmaceutical CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Pharmaceutical CDMO Market Size by Country (2018-2023)
10.4 Middle East & Africa Pharmaceutical CDMO Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Detail
11.1.2 Lonza Business Overview
11.1.3 Lonza Pharmaceutical CDMO Introduction
11.1.4 Lonza Revenue in Pharmaceutical CDMO Business (2018-2023)
11.1.5 Lonza Recent Development
11.2 Catalent
11.2.1 Catalent Company Detail
11.2.2 Catalent Business Overview
11.2.3 Catalent Pharmaceutical CDMO Introduction
11.2.4 Catalent Revenue in Pharmaceutical CDMO Business (2018-2023)
11.2.5 Catalent Recent Development
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Detail
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Pharmaceutical CDMO Introduction
11.3.4 Thermo Fisher Scientific Revenue in Pharmaceutical CDMO Business (2018-2023)
11.3.5 Thermo Fisher Scientific Recent Development
11.4 Samsung Biologics
11.4.1 Samsung Biologics Company Detail
11.4.2 Samsung Biologics Business Overview
11.4.3 Samsung Biologics Pharmaceutical CDMO Introduction
11.4.4 Samsung Biologics Revenue in Pharmaceutical CDMO Business (2018-2023)
11.4.5 Samsung Biologics Recent Development
11.5 Fareva
11.5.1 Fareva Company Detail
11.5.2 Fareva Business Overview
11.5.3 Fareva Pharmaceutical CDMO Introduction
11.5.4 Fareva Revenue in Pharmaceutical CDMO Business (2018-2023)
11.5.5 Fareva Recent Development
11.6 WuXi AppTech
11.6.1 WuXi AppTech Company Detail
11.6.2 WuXi AppTech Business Overview
11.6.3 WuXi AppTech Pharmaceutical CDMO Introduction
11.6.4 WuXi AppTech Revenue in Pharmaceutical CDMO Business (2018-2023)
11.6.5 WuXi AppTech Recent Development
11.7 WuXi Biologics
11.7.1 WuXi Biologics Company Detail
11.7.2 WuXi Biologics Business Overview
11.7.3 WuXi Biologics Pharmaceutical CDMO Introduction
11.7.4 WuXi Biologics Revenue in Pharmaceutical CDMO Business (2018-2023)
11.7.5 WuXi Biologics Recent Development
11.8 Siegfried
11.8.1 Siegfried Company Detail
11.8.2 Siegfried Business Overview
11.8.3 Siegfried Pharmaceutical CDMO Introduction
11.8.4 Siegfried Revenue in Pharmaceutical CDMO Business (2018-2023)
11.8.5 Siegfried Recent Development
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Company Detail
11.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.9.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Introduction
11.9.4 FUJIFILM Diosynth Biotechnologies Revenue in Pharmaceutical CDMO Business (2018-2023)
11.9.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.10 Asymchem
11.10.1 Asymchem Company Detail
11.10.2 Asymchem Business Overview
11.10.3 Asymchem Pharmaceutical CDMO Introduction
11.10.4 Asymchem Revenue in Pharmaceutical CDMO Business (2018-2023)
11.10.5 Asymchem Recent Development
11.11 Pfizer CentreOne
11.11.1 Pfizer CentreOne Company Detail
11.11.2 Pfizer CentreOne Business Overview
11.11.3 Pfizer CentreOne Pharmaceutical CDMO Introduction
11.11.4 Pfizer CentreOne Revenue in Pharmaceutical CDMO Business (2018-2023)
11.11.5 Pfizer CentreOne Recent Development
11.12 Delpharm
11.12.1 Delpharm Company Detail
11.12.2 Delpharm Business Overview
11.12.3 Delpharm Pharmaceutical CDMO Introduction
11.12.4 Delpharm Revenue in Pharmaceutical CDMO Business (2018-2023)
11.12.5 Delpharm Recent Development
11.13 Recipharm
11.13.1 Recipharm Company Detail
11.13.2 Recipharm Business Overview
11.13.3 Recipharm Pharmaceutical CDMO Introduction
11.13.4 Recipharm Revenue in Pharmaceutical CDMO Business (2018-2023)
11.13.5 Recipharm Recent Development
11.14 AGC Pharma Chemicals
11.14.1 AGC Pharma Chemicals Company Detail
11.14.2 AGC Pharma Chemicals Business Overview
11.14.3 AGC Pharma Chemicals Pharmaceutical CDMO Introduction
11.14.4 AGC Pharma Chemicals Revenue in Pharmaceutical CDMO Business (2018-2023)
11.14.5 AGC Pharma Chemicals Recent Development
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Company Detail
11.15.2 Boehringer Ingelheim Business Overview
11.15.3 Boehringer Ingelheim Pharmaceutical CDMO Introduction
11.15.4 Boehringer Ingelheim Revenue in Pharmaceutical CDMO Business (2018-2023)
11.15.5 Boehringer Ingelheim Recent Development
11.16 Vetter
11.16.1 Vetter Company Detail
11.16.2 Vetter Business Overview
11.16.3 Vetter Pharmaceutical CDMO Introduction
11.16.4 Vetter Revenue in Pharmaceutical CDMO Business (2018-2023)
11.16.5 Vetter Recent Development
11.17 Curia
11.17.1 Curia Company Detail
11.17.2 Curia Business Overview
11.17.3 Curia Pharmaceutical CDMO Introduction
11.17.4 Curia Revenue in Pharmaceutical CDMO Business (2018-2023)
11.17.5 Curia Recent Development
11.18 Aenova
11.18.1 Aenova Company Detail
11.18.2 Aenova Business Overview
11.18.3 Aenova Pharmaceutical CDMO Introduction
11.18.4 Aenova Revenue in Pharmaceutical CDMO Business (2018-2023)
11.18.5 Aenova Recent Development
11.19 Porton
11.19.1 Porton Company Detail
11.19.2 Porton Business Overview
11.19.3 Porton Pharmaceutical CDMO Introduction
11.19.4 Porton Revenue in Pharmaceutical CDMO Business (2018-2023)
11.19.5 Porton Recent Development
11.20 Piramal
11.20.1 Piramal Company Detail
11.20.2 Piramal Business Overview
11.20.3 Piramal Pharmaceutical CDMO Introduction
11.20.4 Piramal Revenue in Pharmaceutical CDMO Business (2018-2023)
11.20.5 Piramal Recent Development
11.21 Strides Pharma
11.21.1 Strides Pharma Company Detail
11.21.2 Strides Pharma Business Overview
11.21.3 Strides Pharma Pharmaceutical CDMO Introduction
11.21.4 Strides Pharma Revenue in Pharmaceutical CDMO Business (2018-2023)
11.21.5 Strides Pharma Recent Development
11.22 NextPharma
11.22.1 NextPharma Company Detail
11.22.2 NextPharma Business Overview
11.22.3 NextPharma Pharmaceutical CDMO Introduction
11.22.4 NextPharma Revenue in Pharmaceutical CDMO Business (2018-2023)
11.22.5 NextPharma Recent Development
11.23 Famar
11.23.1 Famar Company Detail
11.23.2 Famar Business Overview
11.23.3 Famar Pharmaceutical CDMO Introduction
11.23.4 Famar Revenue in Pharmaceutical CDMO Business (2018-2023)
11.23.5 Famar Recent Development
11.24 Jubilant
11.24.1 Jubilant Company Detail
11.24.2 Jubilant Business Overview
11.24.3 Jubilant Pharmaceutical CDMO Introduction
11.24.4 Jubilant Revenue in Pharmaceutical CDMO Business (2018-2023)
11.24.5 Jubilant Recent Development
11.25 Alcami
11.25.1 Alcami Company Detail
11.25.2 Alcami Business Overview
11.25.3 Alcami Pharmaceutical CDMO Introduction
11.25.4 Alcami Revenue in Pharmaceutical CDMO Business (2018-2023)
11.25.5 Alcami Recent Development
11.26 Euroapi
11.26.1 Euroapi Company Detail
11.26.2 Euroapi Business Overview
11.26.3 Euroapi Pharmaceutical CDMO Introduction
11.26.4 Euroapi Revenue in Pharmaceutical CDMO Business (2018-2023)
11.26.5 Euroapi Recent Development
11.27 Eurofins
11.27.1 Eurofins Company Detail
11.27.2 Eurofins Business Overview
11.27.3 Eurofins Pharmaceutical CDMO Introduction
11.27.4 Eurofins Revenue in Pharmaceutical CDMO Business (2018-2023)
11.27.5 Eurofins Recent Development
11.28 Avid Bioservices
11.28.1 Avid Bioservices Company Detail
11.28.2 Avid Bioservices Business Overview
11.28.3 Avid Bioservices Pharmaceutical CDMO Introduction
11.28.4 Avid Bioservices Revenue in Pharmaceutical CDMO Business (2018-2023)
11.28.5 Avid Bioservices Recent Development
11.29 BioVectra
11.29.1 BioVectra Company Detail
11.29.2 BioVectra Business Overview
11.29.3 BioVectra Pharmaceutical CDMO Introduction
11.29.4 BioVectra Revenue in Pharmaceutical CDMO Business (2018-2023)
11.29.5 BioVectra Recent Development
11.30 CPL
11.30.1 CPL Company Detail
11.30.2 CPL Business Overview
11.30.3 CPL Pharmaceutical CDMO Introduction
11.30.4 CPL Revenue in Pharmaceutical CDMO Business (2018-2023)
11.30.5 CPL Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Pharmaceutical CDMO Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of API CDMO
Table 3. Key Players of FDF CDMO
Table 4. Key Players of Packaging CDMO
Table 5. Key Players of Clinical CDMO
Table 6. Global Pharmaceutical CDMO Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Pharmaceutical CDMO Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Pharmaceutical CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Pharmaceutical CDMO Market Share by Region (2018-2023)
Table 10. Global Pharmaceutical CDMO Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global Pharmaceutical CDMO Market Share by Region (2024-2033)
Table 12. Pharmaceutical CDMO Market Trends
Table 13. Pharmaceutical CDMO Market Drivers
Table 14. Pharmaceutical CDMO Market Challenges
Table 15. Pharmaceutical CDMO Market Restraints
Table 16. Global Pharmaceutical CDMO Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Pharmaceutical CDMO Market Share by Players (2018-2023)
Table 18. Global Top Pharmaceutical CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmaceutical CDMO as of 2022)
Table 19. Ranking of Global Top Pharmaceutical CDMO Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Pharmaceutical CDMO Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Pharmaceutical CDMO Product Solution and Service
Table 23. Date of Enter into Pharmaceutical CDMO Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Pharmaceutical CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Pharmaceutical CDMO Revenue Market Share by Type (2018-2023)
Table 27. Global Pharmaceutical CDMO Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global Pharmaceutical CDMO Revenue Market Share by Type (2024-2033)
Table 29. Global Pharmaceutical CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Pharmaceutical CDMO Revenue Market Share by Application (2018-2023)
Table 31. Global Pharmaceutical CDMO Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global Pharmaceutical CDMO Revenue Market Share by Application (2024-2033)
Table 33. North America Pharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 34. North America Pharmaceutical CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Pharmaceutical CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 36. Europe Pharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. Europe Pharmaceutical CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Pharmaceutical CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 39. Asia-Pacific Pharmaceutical CDMO Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 40. Asia-Pacific Pharmaceutical CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Pharmaceutical CDMO Market Size by Region (2024-2033) & (US$ Million)
Table 42. Latin America Pharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Latin America Pharmaceutical CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Pharmaceutical CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 45. Middle East & Africa Pharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 46. Middle East & Africa Pharmaceutical CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Pharmaceutical CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 48. Lonza Company Detail
Table 49. Lonza Business Overview
Table 50. Lonza Pharmaceutical CDMO Product
Table 51. Lonza Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 52. Lonza Recent Development
Table 53. Catalent Company Detail
Table 54. Catalent Business Overview
Table 55. Catalent Pharmaceutical CDMO Product
Table 56. Catalent Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 57. Catalent Recent Development
Table 58. Thermo Fisher Scientific Company Detail
Table 59. Thermo Fisher Scientific Business Overview
Table 60. Thermo Fisher Scientific Pharmaceutical CDMO Product
Table 61. Thermo Fisher Scientific Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 62. Thermo Fisher Scientific Recent Development
Table 63. Samsung Biologics Company Detail
Table 64. Samsung Biologics Business Overview
Table 65. Samsung Biologics Pharmaceutical CDMO Product
Table 66. Samsung Biologics Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 67. Samsung Biologics Recent Development
Table 68. Fareva Company Detail
Table 69. Fareva Business Overview
Table 70. Fareva Pharmaceutical CDMO Product
Table 71. Fareva Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 72. Fareva Recent Development
Table 73. WuXi AppTech Company Detail
Table 74. WuXi AppTech Business Overview
Table 75. WuXi AppTech Pharmaceutical CDMO Product
Table 76. WuXi AppTech Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 77. WuXi AppTech Recent Development
Table 78. WuXi Biologics Company Detail
Table 79. WuXi Biologics Business Overview
Table 80. WuXi Biologics Pharmaceutical CDMO Product
Table 81. WuXi Biologics Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 82. WuXi Biologics Recent Development
Table 83. Siegfried Company Detail
Table 84. Siegfried Business Overview
Table 85. Siegfried Pharmaceutical CDMO Product
Table 86. Siegfried Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 87. Siegfried Recent Development
Table 88. FUJIFILM Diosynth Biotechnologies Company Detail
Table 89. FUJIFILM Diosynth Biotechnologies Business Overview
Table 90. FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Product
Table 91. FUJIFILM Diosynth Biotechnologies Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 92. FUJIFILM Diosynth Biotechnologies Recent Development
Table 93. Asymchem Company Detail
Table 94. Asymchem Business Overview
Table 95. Asymchem Pharmaceutical CDMO Product
Table 96. Asymchem Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 97. Asymchem Recent Development
Table 98. Pfizer CentreOne Company Detail
Table 99. Pfizer CentreOne Business Overview
Table 100. Pfizer CentreOne Pharmaceutical CDMO Product
Table 101. Pfizer CentreOne Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 102. Pfizer CentreOne Recent Development
Table 103. Delpharm Company Detail
Table 104. Delpharm Business Overview
Table 105. Delpharm Pharmaceutical CDMO Product
Table 106. Delpharm Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 107. Delpharm Recent Development
Table 108. Recipharm Company Detail
Table 109. Recipharm Business Overview
Table 110. Recipharm Pharmaceutical CDMO Product
Table 111. Recipharm Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 112. Recipharm Recent Development
Table 113. AGC Pharma Chemicals Company Detail
Table 114. AGC Pharma Chemicals Business Overview
Table 115. AGC Pharma Chemicals Pharmaceutical CDMO Product
Table 116. AGC Pharma Chemicals Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 117. AGC Pharma Chemicals Recent Development
Table 118. Boehringer Ingelheim Company Detail
Table 119. Boehringer Ingelheim Business Overview
Table 120. Boehringer Ingelheim Pharmaceutical CDMO Product
Table 121. Boehringer Ingelheim Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 122. Boehringer Ingelheim Recent Development
Table 123. Vetter Company Detail
Table 124. Vetter Business Overview
Table 125. Vetter Pharmaceutical CDMO Product
Table 126. Vetter Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 127. Vetter Recent Development
Table 128. Curia Company Detail
Table 129. Curia Business Overview
Table 130. Curia Pharmaceutical CDMO Product
Table 131. Curia Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 132. Curia Recent Development
Table 133. Aenova Company Detail
Table 134. Aenova Business Overview
Table 135. Aenova Pharmaceutical CDMO Product
Table 136. Aenova Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 137. Aenova Recent Development
Table 138. Porton Company Detail
Table 139. Porton Business Overview
Table 140. Porton Pharmaceutical CDMO Product
Table 141. Porton Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 142. Porton Recent Development
Table 143. Piramal Company Detail
Table 144. Piramal Business Overview
Table 145. Piramal Pharmaceutical CDMO Product
Table 146. Piramal Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 147. Piramal Recent Development
Table 148. Strides Pharma Company Detail
Table 149. Strides Pharma Business Overview
Table 150. Strides Pharma Pharmaceutical CDMO Product
Table 151. Strides Pharma Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 152. Strides Pharma Recent Development
Table 153. NextPharma Company Detail
Table 154. NextPharma Business Overview
Table 155. NextPharma Pharmaceutical CDMO Product
Table 156. NextPharma Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 157. NextPharma Recent Development
Table 158. Famar Company Detail
Table 159. Famar Business Overview
Table 160. Famar Pharmaceutical CDMO Product
Table 161. Famar Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 162. Famar Recent Development
Table 163. Jubilant Company Detail
Table 164. Jubilant Business Overview
Table 165. Jubilant Pharmaceutical CDMO Product
Table 166. Jubilant Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 167. Jubilant Recent Development
Table 168. Alcami Company Detail
Table 169. Alcami Business Overview
Table 170. Alcami Pharmaceutical CDMO Product
Table 171. Alcami Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 172. Alcami Recent Development
Table 173. Euroapi Company Detail
Table 174. Euroapi Business Overview
Table 175. Euroapi Pharmaceutical CDMO Product
Table 176. Euroapi Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 177. Euroapi Recent Development
Table 178. Eurofins Company Detail
Table 179. Eurofins Business Overview
Table 180. Eurofins Pharmaceutical CDMO Product
Table 181. Eurofins Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 182. Eurofins Recent Development
Table 183. Avid Bioservices Company Detail
Table 184. Avid Bioservices Business Overview
Table 185. Avid Bioservices Pharmaceutical CDMO Product
Table 186. Avid Bioservices Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 187. Avid Bioservices Recent Development
Table 188. BioVectra Company Detail
Table 189. BioVectra Business Overview
Table 190. BioVectra Pharmaceutical CDMO Product
Table 191. BioVectra Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 192. BioVectra Recent Development
Table 193. CPL Company Detail
Table 194. CPL Business Overview
Table 195. CPL Pharmaceutical CDMO Product
Table 196. CPL Revenue in Pharmaceutical CDMO Business (2018-2023) & (US$ Million)
Table 197. CPL Recent Development
Table 198. Research Programs/Design for This Report
Table 199. Key Data Information from Secondary Sources
Table 200. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Pharmaceutical CDMO Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Pharmaceutical CDMO Market Share by Type: 2022 VS 2033
Figure 3. API CDMO Features
Figure 4. FDF CDMO Features
Figure 5. Packaging CDMO Features
Figure 6. Clinical CDMO Features
Figure 7. Global Pharmaceutical CDMO Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 8. Global Pharmaceutical CDMO Market Share by Application: 2022 VS 2033
Figure 9. Pharmaceutical Company Case Studies
Figure 10. Biotechnology Company Case Studies
Figure 11. Other Case Studies
Figure 12. Pharmaceutical CDMO Report Years Considered
Figure 13. Global Pharmaceutical CDMO Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 14. Global Pharmaceutical CDMO Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 15. Global Pharmaceutical CDMO Market Share by Region: 2022 VS 2033
Figure 16. Global Pharmaceutical CDMO Market Share by Players in 2022
Figure 17. Global Top Pharmaceutical CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmaceutical CDMO as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Pharmaceutical CDMO Revenue in 2022
Figure 19. North America Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. North America Pharmaceutical CDMO Market Share by Country (2018-2033)
Figure 21. United States Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Canada Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Pharmaceutical CDMO Market Share by Country (2018-2033)
Figure 25. Germany Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. France Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. U.K. Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Italy Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Russia Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Nordic Countries Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Pharmaceutical CDMO Market Share by Region (2018-2033)
Figure 33. China Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Japan Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. South Korea Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Southeast Asia Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. India Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Australia Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Pharmaceutical CDMO Market Share by Country (2018-2033)
Figure 41. Mexico Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Brazil Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Pharmaceutical CDMO Market Share by Country (2018-2033)
Figure 45. Turkey Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Saudi Arabia Pharmaceutical CDMO Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Lonza Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 48. Catalent Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 49. Thermo Fisher Scientific Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 50. Samsung Biologics Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 51. Fareva Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 52. WuXi AppTech Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 53. WuXi Biologics Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 54. Siegfried Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 55. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 56. Asymchem Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 57. Pfizer CentreOne Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 58. Delpharm Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 59. Recipharm Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 60. AGC Pharma Chemicals Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 61. Boehringer Ingelheim Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 62. Vetter Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 63. Curia Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 64. Aenova Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 65. Porton Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 66. Piramal Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 67. Strides Pharma Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 68. NextPharma Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 69. Famar Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 70. Jubilant Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 71. Alcami Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 72. Euroapi Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 73. Eurofins Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 74. Avid Bioservices Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 75. BioVectra Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 76. CPL Revenue Growth Rate in Pharmaceutical CDMO Business (2018-2023)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries